// App-Quantinova.ai

: Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).

Researchers

Presenter

  • Anderley Gordon

Principal Investigators

  • Avani Athauda

  • Andrew Woolston

  • Sonia Mansukhani

  • Matt Dunstan

  • Nikoletta Petrou

  • Komel Khabra

  • Retchel Lazaro-Alcausi

  • Richard Crux

  • Victoria Borja

  • Ruwaida Begum

  • Isma Rana

  • Sheela Rao

  • Sacheen Kumar

  • David Cunningham

  • Ian Chau

  • Naureen Starling

  • M. Asif Chaudry

  • Marco Gerlinger

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden Hospital, Surrey, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT03399071

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved